chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Sick; Initial information regarding this unsolicited valid non-serious social media case received from a consumer (patient) on 05-Dec-2020.  This case involves a patient with unknown demographics who experienced sick (Illness) when received vaccine INFLUENZA VACCINE.  Relevant medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, (unknown latency) the patient experienced sick (Illness) whenever he or she took the INFLUENZA VACCINE (flu shot) flu shot. The patient did not take any shots again this year, up until last year the patient was took flu shot still got sick. So the last 2 years, no shot and not had been sick and now the patient not around very many people to be exposed.  Relevant laboratory test not reported.  It was not reported if the patient received a corrective medication.  At the time of reporting, the outcome was unknown for the reported event.  There will be no information available on batch number for this case.
As per employee felt dizzy, warmth to head, and nausea. Employee states symptoms subsided approx 1 hour after onset of symptoms. Employee states she was escorted to medical office to sit down and was provided with an ice compress.
the patient was vaccinated with M-M-R II intramuscularly; No adverse symptoms reported; This spontaneous report was received from a pharmacist referring to a patient of an unknown age and an unknown gender. Information about pertinent medical history, drug reactions/allergies and concomitant medication was not reported.  On an unknown date, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) intramuscularly (dose detail, lot # and expiration date were not reported) for prophylaxis (incorrect route of product administration). No adverse symptoms were reported.
Loss of energy, fatigue, brain fog, very emotional, anxiety and depression. Myers Cocktail IV, prescription steroids. COVID Antibodies over 2500. Nothing seems to be helping my condition.
blood sugar was averaging 200 or even up to 300 after a vaccine or booster; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 62-year-old female patient received BNT162b2 (BNT162B2), on 30Jul2021 as dose 2, single (Lot number: FA7484), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Severe osteoporosis", start date: 2020, stop date: 2021. The patient's family history included: "type 2 diabetic" (unspecified if ongoing), notes: Both parents were adult onset type 2 diabetes. Concomitant medication(s) included: METFORMIN taken for diabetes mellitus; GLIPIZIDE taken for diabetes mellitus. Vaccination history included: BNT162b2 (DOSE 1, SINGLE; lot number: EW0191, in the left arm), administration date: 09Jul2021, when the patient was 62-year-old, for COVID-19 immunisation, reaction(s): "blood sugar was averaging 200 or even up to 300 after a vaccine or booster"; Flu shot (This was years ago and she does not have a manufacturer, lot or expiration), for immunization. The following information was reported: BLOOD GLUCOSE INCREASED (medically significant) with onset 2021, outcome "unknown", described as "blood sugar was averaging 200 or even up to 300 after a vaccine or booster". The patient underwent the following laboratory tests and procedures: Blood glucose: (2021) High, notes: each time she had a Pfizer COVID-19 vaccine or booster, she always had high blood sugars; (2021) averaging 200 or even up to 300, notes: blood sugar was averaging 200 or even up to 300 after a vaccine or booster; Glycosylated haemoglobin: (2021) 9; (2021) 6.6; (2021) 6.4.
Red arm, rash 3 x 3 inches at injection site, very warm to the touch, itchy. Normal after four days.
This vaccine was given too early.  The child is age 14. This should be given at age 16.   Spoke with mother, and the child had  no reaction, or injury.
Information has been received from a female who on an unspecified date was vaccinated with a dose of ZOSTAVAX (Merck). Subsequently the patient experienced shingles. At the time of report, the patient's outcome was unknown. No further information is available.
This spontaneous report as received from a certified medical assistant refers to an unspecified number of patients of unknown age and gender. No information regarding the patients' medical history, concomitant medications and drug reactions or allergies was reported. On an unknown date in 2015, an unspecified number of patients might have been vaccinated with a dose of improperly stored GARDASIL, lot # K007828, expiration date 02-MAR-2017 (route of administration, doses, dose numbers not reported). GARDASIL was improperly exposed to temperatures of 90F for 24 hours on 28-MAY-2015 and 91F for 24 hours on 29-MAY-2015. No adverse events were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Pt given approx 1/2 dose Rotavirus vaccine & stopped breathing, appeared to be choking resolved with blow to back while prone, lasted < 1 min.
Feb2021: blood clot in Lt leg.; Lt leg pain; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An elderly male patient received BNT162b2 (BNT162B2), on 25Feb2021 as dose 1, single (Batch/Lot number: unknown), in right deltoid for covid-19 immunisation. The patient's relevant medical history included: "Prostate cancer", start date: May2001, stop date: 2010, notes: 91 seeds placed in grown around CT scan, Start date: summer 2010; "Heart attack", start date: Sep2005 (ongoing), notes: Install 3 stents, under withheld. The patient took concomitant medications. The following information was reported: THROMBOSIS (hospitalization, medically significant) with onset Feb2021, outcome "not recovered", described as "Feb2021: blood clot in Lt leg."; PAIN IN EXTREMITY (hospitalization) with onset Feb2021, outcome "recovered with sequelae", described as "Lt leg pain". The patient was hospitalized for pain in extremity (hospitalization duration: 3 day(s)). The events "feb2021: blood clot in lt leg." and "lt leg pain" required emergency room visit. The patient underwent the following laboratory tests and procedures: Computerised tomogram: (unspecified date) Unknown, notes: Many times; INC (2-3): (unspecified date) 1.7 - 4.4, notes: Every 2 weeks - 1/month; Platelet factor 4: (Feb2021) Factor V, notes: Ultrasound to check for clots in legs; Ultrasound scan: (unspecified date) Yes, notes: Tet for blood clots. Therapeutic measures were taken as a result of thrombosis, pain in extremity.  Clinical course: Patient was factor V on warfarin and for leg pain took Warfarin.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Fever, neck and head ache,dizziness, chills 3rd day to dizzy to drive or work.Advil ever 4hrs and dramamine for the dizziness
Moderna booster administered 2 months early.   First and second dose given 11/2021.
Received Flu vac on 9/26/23 @0845, site left arm. 9/27/23@ 0600 woke up with redness at injection site 4 inches in diameter, warm to touch, tender, not itchy. Denies any rashes and no respiratory distress. Have headache and body aches. All symptoms are resolved after 24 hours. Applied ice pack to affected site and took Advil dual action Q 4 hours
PT HAD VACCINE ON 10-23-21. DEVELOPED BLOOD CLOT THAT LODGED IN KIDNEY AND WAS HOSPITALIZED ON 10-31-2021 . PT HAS ONGOING KIDNEY DAMAGE.
Patient's eyes were sore the night of the shots. That soreness lasted until midday the following day. Also, developed heavy foot in my left leg. That too has also subsided.
3 days post injection redness and blisters at injection site with tenderness at site. No treatment administered at this time. Pt to return to office on 5/25/16 for reevaluation.
A report has been received from a Physician concerning a 2 month old, Male subject, who had been receiving Nasal FLUMIST. FLUMIST started on 11-Sep-2012. The patient experienced positive flu test, cough, temperature of 103 degrees F and congestion on 19-Oct-2012. The report was considered to be non-serious. Summary of follow-up information received by AstraZeneca/MedImmune 01-Nov-2012 from Physician via health care professional: Start date added for the events of cough and congestion. Stop date added and outcome updated as recovered for the events of temperature 103 degrees F, cough, congestion and positive flu test. Date of birth updated for the patient.
Patient complained of "Hot everywhere, chest and heart racing" Denies SOB  Bp 139/78, hr 64, oxygen level 99% on room air. EMS at patient's side at clinic, evaluated and discussed symptoms with patient. No interventions needed at this time and patient monitored for an additional 15 mins.  VS remain stable and at 1045a, BP was 142/76, oxygen level 100%, HR 58  with patient states feeling better and feels she can drive home. EMS released patient.
This report to VAERS provides the following narrative: A report has been received from VAERS (Health Authority) concerning an 18 year old, male patient. The patient's concurrent disease(s) included penicillin allergy. The patient had been received nasal FLUMIST started on 29-Aug-2006. The patient experienced Guillain Barre syndrome which started on 30-Aug-2006. Patient admitted to hospital on 02-Sep-2006 with bilateral upper and lower extremity (ascending) weakness, calf pains and intermittent tingling of feet. Vital signs normal, antalgic gait, walks only with assistance. Diagnosed with variant of Guillain Barre, treated with IV Immune Globulin. Remains in hospital, but transferred from ICU to medical ward. Abnormal study electrophysiologic evidence of severe motor greater than sensory acquired multifocal sensorimotor peripheral neuropathy with axonal greater than demyelinating features. Given the history this likely represents GBS. The prognosis for recovery with predominant axonal features would probably be a protracted course. Presented with progressive weakness and numbness in hands and feet time 3 days. Weakness began first then tenderness in his gastrocs and numbness working its way distal to proximal up to his elbow and knees. History of productive cough since beginning of basic training. No fever, chills or night sweats. Exposed to others with diarrhea but he has not had diarrhea. Hospital course continued to have weakness in lower extremities mainly feet, also decreased grip strength with no change during ICU stay. Treated with IVIG for 3 days. No change in neuro symptoms or respiratory function transferred from ICU to medical floor and subsequently discharged. At the time of reporting, the event of Guillain Barre syndrome was ongoing. The reporter considered the event of Guillain Barre syndrome to be serious due to hospitalization. Diagnostic test details are available.
Vaccine administered to pt at 1805. Pt observed for 30 minutes due to history of allergies. AT 1835 pt reported feeling "cold, nauseous" and reported feeling "every side effect on the handout."  Staff provided juice and graham cracker and assessed vitals. Vitals within patient's baseline. Pt then reported "back pain" and described ita s "squeezing"  Staff performed 12 lead EKG.  EKG results within patient's baseline.  Pt kept for another 10 mins and observed. Staff advised pt  to contact doctor and go to ER if symptoms persist. Pt reported feeling better and comfortable with going home.  Pt went home after a total of 45 minutes of observation with daughter.
Developed a red, swollen left deltoid measuring 7cm by 5cm. Began the morning of 11/17/2016 and reached its maximum size by the afternoon. Recommended compresses and watching the area. In the future he may need to see an allergist regarding his next dose.
injection site pain, arm pain lasted a few days; general muscle pain lasted longer than a few days; general fatigue lasted about 7 days.
10JUL96 16 days p/vax pt exp myalgia;dx of post vaccination GBS variant;10 days later diff getting up from squatting posture;25JUL96 exp proximal weakness in upper & lower limbs,diff walking;resp infect, swelling all over body;diff breathin
My blood levels and heart were affected after I received the vaccine. I received one unit of blood in Feb2023; My blood levels and heart were affected after I received the vaccine. I received one unit of blood in Feb2023; This is a spontaneous report received from a contactable reporter(s) (Nurse) from medical information team, Program ID:. The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2, bnt162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete; unknown manufacturer), for COVID-19 Immunisation. The following information was reported: BLOOD DISORDER (medically significant), CARDIAC DISORDER (non-serious), outcome "unknown" and all described as "My blood levels and heart were affected after I received the vaccine. I received one unit of blood in Feb2023". The patient underwent the following laboratory tests and procedures: Blood test: Unknown results. Therapeutic measures were taken as a result of blood disorder. Clinical course: Patient enquired: Was there any literature on Bivalent Covid -19 mRNA booster. Patients blood levels and heart were affected after received the vaccine. Than received one unit of blood in Feb2023.  The information on the batch/lot number for bnt162b2, bnt162b2 omi ba.4-5 has been requested and will be submitted if and when received.; Sender's Comments: Based on the information available, a possible contributory role of the suspect drug cannot be excluded for the reported event Blood disorder.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
Received 3rd dose by error; 1st dose on 19-NOV-2019, 2nd dose 09-NOV-2022; This case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 63-year-old female patient who received Herpes zoster (Shingrix) (batch number NR5SZ, expiry date 22nd October 2022) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on 19th November 2019).   On 26th May 2021, the patient received the 3rd dose of Shingrix. On 9th November 2020, the patient received the 2nd dose of Shingrix. On 9th November 2020, not applicable after receiving Shingrix and unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On 26th May 2021, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered and drug dose administration interval too long were unknown.   Additional Information: GSK Receipt Date: 04-MAY-2022 Reporter's Comment: Pharmacist was looking for information if a patient received Shingrix third dose by error.  Consented to follow up by email. Additional Supportive Information: The patient received 3rd dose of Shingrix by error, which led to extra dose administered. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule.
sore arm at site of injection, moderate muscle aches throughout body especially in shoulders, moderate fatigue, mild headache; symptoms began around 9:00pm the evening of vaccination, more prominent symptoms as the next day (4/6/21) progresses.
Local reaction to ADACEL in Lt deltoid and PPD placed in left forearm. Redness, itchiness and swelling to deltoid & forearm.
Received the Moderna covid booster vaccine. (Moderna was the original vaccine provider as well.) After booster I had illness symptoms of joint and muscle achiness not experienced originally, but that was not particularly concerning. I also could feel some sort of differences the way my heart normally behaves. Typically I am not consciously aware of my heartbeat but assume it remains operational. However since the booster I can "feel" it somewhat regularly and it seems to be beating slightly differently. It's somewhat subtle but persistent. The joint and muscle achiness have gone away, but the heart differences remain so far, so as a precaution I haven't resumed normal physical exercise/activity yet.
Low white blood count; This spontaneous case was reported by a consumer and describes the occurrence of WHITE BLOOD CELL COUNT DECREASED (Low white blood count) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product VENETOCLAX (VENCLEXTA) for an unknown indication.    No Medical History information was reported.   On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 22-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started VENETOCLAX (VENCLEXTA) (Oral) at an unspecified dose. On an unknown date, the patient experienced WHITE BLOOD CELL COUNT DECREASED (Low white blood count). At the time of the report, WHITE BLOOD CELL COUNT DECREASED (Low white blood count) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, White blood cell count: Low.         No relevant concomitant medications were reported. The patient was taking VENCLEXTA, however physician took her off temporarily due to low white blood cell count. No treatment medication reported.   It was unknown if patient was enrolled in Covid-10 Vaccine trial.  The reporters causality for the event with VENCLEXTA was not provided.
pain in my upper arm; felt sick; miserable headache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID. The reporter is the patient.  A 33-year-old female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 1st, My arm was a little sore after the first shot), for Covid-19 immunization, reaction(s): "My arm was a little sore after the first shot". The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "pain in my upper arm"; MALAISE (non-serious), outcome "unknown", described as "felt sick"; HEADACHE (non-serious), outcome "unknown", described as "miserable headache".  Additional information: How scary Covid has been How relieved she was to get my first [Pfizer] Covid vaccine How great the nurse was at giving shots (she was terrified, she hate shots and needles) was great , she had given me the shot e fire she realized it .she did not even feel it. Then as she sat there for 15 mins she was so worried about the possible side effects. The short film she just watched mentioned the most common side effects and that fear/concern came back. Her arm was a little sore after the first shot. Her second [Pfizer] Covid vaccines experience was not as good as the first. She did experience pain in her upper arm , she felt sick had a miserable headache The two [Pfizer] boosters she had received have been unpleasant post injection side effects have been stronger the last one she was miserable. She just kept thinking this sucks but she have heard that Covid is really horrible so she was glad she dont have that.   The information on the batch/lot number for [BNT162B2] has been requested and will be submitted if and when received.
shingles; break out on my arm; This case was reported by a consumer and described the occurrence of shingles in a adult patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 25th August 2020, the patient received Shingles vaccine. On an unknown date, less than 3 weeks after receiving Shingles vaccine, the patient experienced shingles and eruption of limbs. On an unknown date, the outcome of the shingles and eruption of limbs were unknown.   It was unknown if the reporter considered the shingles and eruption of limbs to be related to Shingles vaccine.  Additional details were provided as follows: The age at vaccination was not reported. After receiving Shingles vaccine, the patient had shingles. The patient had a break out on his/her arm. This case was linked with case US2020AMR183114, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR183114:copy for second patient
Information has been received from a physician concerning her 17 year old niece who on approximately 15-MAY-2008 was vaccinated with the second dose of GARDASIL (lot number not reported). Subsequently the patient underwent a pap smear between the first and second dose that showed stage 1 cervical dysplasia. At the time of the report the patient had not recovered. Additional information has been requested.
Fatigue; lymph node swelling; This is a spontaneous report from a contactable nurse. A 52-year-old male patient started to receive BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: unknown) intramuscular from 06Jan2021 10:45 to 06Jan2021 10:45 at single dose for COVID-19 vaccination. Medical history included idiopathic epilepsy. Concomitant medication included carbamazepine. On 06Jan2021 at 17:00, the patient had fatigue two days after as well lymph node swelling in armpit of arm where second dose administered. The patient also stated that with first dose from 15Dec2020 to 15Dec2020 for COVID-19 vaccination, the patient had soreness in his arm with no other symptoms. Outcome of the events was not recovered.  Information on the lot/ batch number has been requested.